Tutorials › Group Sequential Methods and Sample Size Re-Estimation › P-Values Under Actual Interim Look Timing

Orderings and p-Values After Early Stopping · Tutorial 282 of 699

P-Values Under Actual Interim Look Timing

Recalculate a stagewise p-value using the actual information times, the applicable design boundaries, and the joint null distribution of the sequential statistics.

Advanced 12 min read

What You'll Learn

  • Distinguish fixed look-specific boundaries from boundaries defined as a function of information time.
  • Reconstruct the joint null distribution using the information times that actually occurred.
  • Calculate a stagewise p-value for an observed efficacy stop under an explicit ordering.
  • Compare p-values computed from planned and actual look schedules.
  • Identify when outcome-dependent timing requires modeling the timing process itself.
  • Check whether the observed look, boundary, and assumed canonical model are consistent.

Why Actual Look Timing Matters

A sequential p-value is a probability under the stopping rule that was actually applied. If an interim analysis occurs at a different information time from the planned time, the standardized statistic at that look may still have a standard normal marginal distribution under the null, but its dependence on statistics at other looks changes. Since a stagewise p-value includes probabilities of crossing at earlier looks as well as at the observed look, this change in dependence can change the p-value.

The boundary convention matters too. Some designs assign a fixed boundary to each numbered look. Others specify a boundary function of information time. In the first case, use the boundary assigned to the look that actually occurred. In the second, evaluate the specified function at the actual information time. Do not silently substitute a boundary from the planned schedule or redesign the boundary after seeing the data.

Definition: For this tutorial, consider an upper-tail efficacy design with \(K\) possible looks. At actual information times \(0<t_1<\cdots<t_K\), the statistic \(Z_i\) is compared with the applicable efficacy boundary \(b_i\). The trial stops for efficacy at look \(i\) if \(Z_i\ge b_i\) and \(Z_j<b_j\) at every earlier look \(j<i\). For an observed efficacy stop at look \(k\) with statistic \(z\), the upper-tail stagewise ordering treats every efficacy stop at an earlier look as at least as extreme as this outcome, and orders outcomes at look \(k\) by decreasing \(Z_k\). Its p-value is the null probability of the outcomes at least as extreme under this ordering.

This explicit ordering is important: a sequential p-value is not determined by the observed \(z\)-statistic alone. If the analysis also has futility stops, two-sided boundaries, or a different ordering, the relevant outcome regions must reflect those features. The calculations below focus on the stated upper-tail efficacy ordering.

Model and Calculation Under the Actual Schedule

Assume the canonical Gaussian model under \(H_0\): information time is measured on a common scale, the score process has independent increments, and standardization gives \(Z_i\sim N(0,1)\) at each look. For deterministic information times, its joint null distribution satisfies

$$ \operatorname{Cov}_0(Z_i,Z_j) = \sqrt{\frac{t_i}{t_j}}, \qquad i<j. $$

Thus, for two looks, the correlation is \(\rho=\sqrt{t_1/t_2}\). This is generally not the correlation obtained by inserting the planned information times when the actual times differ. The model also assumes the information times are fixed in advance or are determined independently of the accumulating outcomes. If the timing itself responds to the emerging results, conditioning on the observed schedule alone may not give the correct null distribution.

For an efficacy stop at look \(k\) with observed statistic \(z\), let \(C_j\) denote the event of an efficacy stop at look \(j\). Under the ordering just defined, the p-value is

$$ p_{\mathrm{stage}}(z,k) = \sum_{j=1}^{k-1}P_0(C_j) + P_0\!\left( Z_1<b_1,\ldots,Z_{k-1}<b_{k-1}, \ b_k\le Z_k,\ Z_k\ge z \right). $$

Because the observed outcome is an efficacy stop, \(z\ge b_k\), so the final two requirements are equivalent to \(Z_k\ge z\). This probability is evaluated using the joint distribution at the actual information times and the boundaries applicable under the design.

For two looks and an observed efficacy stop at look 2, the result reduces to

$$ p_{\mathrm{stage}}(z,2) = P_0(Z_1\ge b_1) + P_0(Z_1<b_1,\ Z_2\ge z). $$

These two events are disjoint: the first is an efficacy stop at look 1; the second is no efficacy stop at look 1 followed by a look-2 statistic at least as large as the observed value. Under the canonical model, the second probability can be computed as

$$ \int_{-\infty}^{b_1} \phi(x) \left[ 1-\Phi\!\left( \frac{z-\rho x}{\sqrt{1-\rho^2}} \right) \right]\,dx, \qquad \rho=\sqrt{\frac{t_1}{t_2}}, $$

where \(\phi\) and \(\Phi\) are the standard normal density and cumulative distribution function. The conditional distribution used here is \(Z_2\mid Z_1=x\sim N(\rho x,1-\rho^2)\). The formula follows by integrating the conditional probability \(P_0(Z_2\ge z\mid Z_1=x)\) over values \(x<b_1\), then adding the disjoint probability of an earlier efficacy stop.

Worked Example: An Efficacy Stop at the First Actual Look

Suppose a hypothetical trial has one-sided upper-tail efficacy monitoring. Its first look occurs at actual information time \(t_1=0.30\), rather than the planned \(0.40\). The design specifies a fixed first-look boundary \(b_1=2.10\), and the observed statistic is \(z_1=2.18\). Assume the canonical Gaussian null model and that no earlier analysis occurred.

The observed statistic exceeds the boundary, since \(2.18\ge2.10\), so the trial stops for efficacy at this look. Under the stagewise ordering, there are no earlier efficacy stops to include. The one-look null probability is therefore

$$ p_{\mathrm{stage}} = P_0(Z_1\ge2.18) = 1-\Phi(2.18) \approx 0.0146. $$

The p-value is about 0.0146. Here the changed timing does not alter the standard normal marginal distribution at the first look, given the stated model and standardization; it does determine which analysis occurred and which fixed look-specific boundary applies. With multiple looks, actual timing also changes the joint distribution used to account for earlier stopping.

Worked Example: Planned and Actual Schedules Give Different Stagewise Probabilities

Consider a hypothetical two-look upper-tail design with fixed boundaries \(b_1=b_2=1.00\). The planned information times are \(t_1=0.50\) and \(t_2=1.00\). In the trial as conducted, the first look instead occurs at \(t_1=0.25\), while the second occurs at \(t_2=1.00\). The observed outcome is an efficacy stop at look 2 with \(z_2=1.00\), and \(Z_1<1.00\).

Under the actual schedule, the correlation is

$$ \rho_{\mathrm{actual}} = \sqrt{\frac{0.25}{1.00}} = 0.500. $$

Because the observed statistic equals the second-look boundary, the stagewise p-value is the probability of crossing the first boundary or, without an earlier crossing, reaching at least \(1.00\) at the second look:

$$ p_{\mathrm{actual}} = P_0(Z_1\ge1.00) + P_0(Z_1<1.00,\ Z_2\ge1.00) \approx 0.255. $$

The approximation is obtained by evaluating the bivariate normal probability with correlation \(0.500\). As a check on the event, the sum is \(P_0(Z_1\ge1.00\ \text{or}\ Z_2\ge1.00)\): if the first statistic is below the boundary, the second must reach it; otherwise the trial has already stopped at the first look.

If the planned correlation were incorrectly used, it would be

$$ \rho_{\mathrm{planned}} = \sqrt{\frac{0.50}{1.00}} \approx 0.707, \qquad P_0(Z_1\ge1.00\ \text{or}\ Z_2\ge1.00) \approx 0.235. $$

The planned-schedule calculation gives a different result because it uses a different joint null distribution. The applicable fixed boundaries have not changed in this example; the actual information times change the dependence between looks. The reported stagewise p-value for this observed stopping rule is therefore the value based on the actual schedule, approximately 0.255.

Boundary Conventions and Practical Checks

Before calculating, establish what the protocol means by a boundary when timing shifts. If \(b_i\) is a fixed value attached to look number \(i\), use that value at the actual \(i\)th look. If the boundary is specified as \(b(t)\), evaluate \(b(t_i)\). These are different design conventions; neither should be assumed from the numerical boundary alone. A boundary table calculated only at planned times does not automatically define a boundary at every possible actual time.

Worked Example: Applying a Boundary Function at the Actual Time

Suppose a hypothetical design explicitly defines its first-look boundary by \(b(t)=2.80-0.50t\), where \(t\) is the information fraction. The actual first look occurs at \(t_1=0.32\), and the observed statistic is \(z_1=2.71\). Assume the canonical model, a single efficacy comparison at this first look, and no earlier stopping opportunity.

The applicable boundary is

$$ b(0.32)=2.80-(0.50)(0.32)=2.64. $$

Since \(2.71\ge2.64\), this is an efficacy stop. There are no earlier efficacy regions in the ordering, so

$$ p_{\mathrm{stage}} = P_0(Z_1\ge2.71) = 1-\Phi(2.71) \approx 0.00336. $$

Using the boundary that the function assigns at the actual time is appropriate because the design explicitly defines it that way. If instead the protocol assigned a fixed first-look boundary of, for example, 2.75, that fixed value would apply and \(2.71\) would not cross it. The boundary convention must be resolved before classifying the observed outcome or calculating its p-value.

A practical calculation should be checked against the data and design record, not just against software output. Confirm the actual information times, their ordering, the look number, the stopping status, the boundary convention, and the observed statistic. Then verify that the covariance matrix is positive definite and consistent with those times. For example, with two looks the calculated correlation must be between 0 and 1; a value outside that range signals an error in the time inputs or formula.

Numerical integration or multivariate normal software can evaluate the required probabilities, but the integration limits and event region must represent the stopping rule. Simulation can be a useful check: simulate joint statistics under the null at the actual times, apply the actual boundaries, and estimate the proportion in the stagewise tail region. Agreement within Monte Carlo error is a diagnostic, not a substitute for specifying the correct probability.

What Recalculation Does—and Does Not—Do

Recalculating the p-value under actual timing answers a specific question: under the assumed null model and the stopping rule as applied, how much null probability lies in outcomes at least as extreme as the observed stopped outcome under the stated ordering? It does not by itself restore a nominal type I error rate. If a design's boundaries were calibrated for one schedule and actual timing changes, the probability of crossing a boundary under \(H_0\) may differ from the planned error rate. A recalculated p-value describes the observed outcome using the actual rule; it does not retroactively recalibrate that rule.

The main alternative is to analyze using planned look times and their planned joint distribution. That is appropriate only when those times genuinely describe the analyses conducted or when a prespecified design-based convention justifies that analysis. Another possibility is to use a design explicitly defined by an information-time boundary function. In either case, the analysis must match the protocol and the actual stopping mechanism; choosing whichever schedule yields a smaller p-value is not valid.

The canonical Gaussian calculation also has limits. It may be inadequate if information is not correctly measured, the test statistic is not well approximated by the assumed process, increments are not independent, or actual analysis timing depends on emerging outcomes in a way not represented by the model. With outcome-dependent timing, the timing process may need to be included in the null probability calculation. Merely substituting the observed times into a fixed-time covariance formula does not automatically account for selection induced by that timing.

A common mistake is to argue that the same observed \(Z_k\) must imply the same sequential p-value because each \(Z_i\) has a standard normal null marginal distribution. The correction is that the stagewise p-value includes earlier stopping regions and their joint probability with the observed look. Marginal distributions alone do not determine that probability: the actual information times determine the dependence between looks and hence the probability of the ordered stopped outcomes.

Key takeaway: Use actual information times to construct the joint null distribution, use the boundary convention specified by the design, and calculate the probability of the stagewise tail region for the stopping rule that was applied. If timing depends on the outcomes, model that dependence rather than treating the observed schedule as automatically fixed.

Check Your Understanding

Answer each question using the upper-tail stagewise ordering defined above.

  1. For two looks with actual information times \(t_1=0.36\) and \(t_2=1.00\), what is the canonical null correlation between \(Z_1\) and \(Z_2\)?
  2. A design assigns fixed boundaries to look numbers. The first look is delayed, but it remains the first look. Which boundary applies: the first-look boundary or a boundary interpolated from the planned information fraction?
  3. Why is \(P_0(Z_2\ge z)\) alone generally not the stagewise p-value for an efficacy stop at look 2?
  4. A boundary is specified by \(b(t)=2.5+0.4t\). Evaluate it at actual information fraction \(t=0.30\).
  5. If look timing is changed in response to emerging treatment results, is substituting the observed times into the fixed-time covariance formula necessarily sufficient? Explain.

Solutions. (1) \(\rho=\sqrt{0.36/1.00}=0.600\). (2) The first-look boundary applies, because the design assigns a fixed boundary to the numbered look; do not interpolate unless the design specifies a time-dependent boundary. (3) The stagewise p-value also includes the probability of efficacy stops at earlier looks, and the no-earlier-crossing condition at look 2 must be represented in the joint event. (4) \(b(0.30)=2.5+(0.4)(0.30)=2.62\). (5) No. Outcome-dependent timing can induce selection; the null calculation may need to model the timing process jointly with the statistics rather than treating the observed times as fixed.

Clinical Biostats